Consequently, immune checkpoint inhibitors like anti-CTLA-4, anti-PD-1, and anti-PD-L1 can bind to these inhibitory receptors, effectively restoring the immune response against cancer cells, making them suitable therapeutic targets [186]. Here, CTLA4 is linked to cancer.